Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.68 +0.10 (+0.60%)

Streaming Delayed Price Updated: 2:16 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States

September 26, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners

September 20, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

September 14, 2023

From Bausch + Lomb Corporation

Via Business Wire

Earnings Preview: Bausch & Lomb ↗

August 01, 2023

Via Benzinga

Analyst Ratings for Bausch & Lomb ↗

July 24, 2023

Via Benzinga

Analyst Ratings for Bausch & Lomb ↗

July 03, 2023

Via Benzinga

9 Analysts Have This to Say About Bausch & Lomb ↗

May 19, 2023

Via Benzinga

Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

September 12, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

September 11, 2023

Via ACCESSWIRE

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

September 11, 2023

From Bausch + Lomb Corporation

Via Business Wire

Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

September 08, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®

September 06, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting

September 06, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference

August 29, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®

August 24, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook

August 02, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Solidifies Leadership Team

August 01, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2

July 11, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink ↗

July 06, 2023

Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)...

Via Benzinga

Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops

July 06, 2023

From Bausch + Lomb Corporation

Via Business Wire

Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗

June 30, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories ↗

June 30, 2023

New York Post

Via Benzinga

Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis ↗

June 30, 2023

Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE:

Via Benzinga

Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)

June 30, 2023

Via ACCESSWIRE

Bausch + Lomb Will Acquire XIIDRA®

June 30, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

June 12, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting

June 08, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States

June 06, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States

June 05, 2023

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Key Leadership Changes

June 01, 2023

From Bausch + Lomb Corporation

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.